We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · August 26, 2020

Bempegaldesleukin Plus Nivolumab in Untreated Unresectable or Metastatic Melanoma

Future Oncology (London, England)


Additional Info

Future Oncology (London, England)
Bempegaldesleukin Plus Nivolumab in Untreated, Unresectable or Metastatic Melanoma: Phase III PIVOT IO 001 Study Design
Future Oncol 2020 Jul 29;[EPub Ahead of Print], NI Khushalani, A Diab, PA Ascierto, J Larkin, S Sandhu, M Sznol, HB Koon, A Jarkowski, M Zhou, P Statkevich, WJ Geese, GV Long

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading